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Wilson’s Disease: Changes in Methionine Metabolism
and Inflammation Affect Global DNA Methylation in
Early Liver Disease
Valentina Medici,1 Noreene M. Shibata,1 Kusum K. Kharbanda,2 Janine M. LaSalle,3 Rima Woods,3 Sarah Liu,1
Jesse A. Engelberg,4 Sridevi Devaraj,5 Natalie J. T€or€ok,1 Joy X. Jiang,1 Peter J. Havel,6,7 Bo L€onnerdal,7
Kyoungmi Kim,8 and Charles H. Halsted1
Hepatic methionine metabolism may play an essential role in regulating methylation sta-
tus and liver injury in Wilson’s disease (WD) through the inhibition of S-adenosylhomo-
cysteine hydrolase (SAHH) by copper (Cu) and the consequent accumulation of
S-adenosylhomocysteine (SAH). We studied the transcript levels of selected genes related
to liver injury, levels of SAHH, SAH, DNA methyltransferases genes (Dnmt1, Dnmt3a,
Dnmt3b), and global DNA methylation in the tx-j mouse (tx-j), an animal model of WD.
Findings were compared to those in control C3H mice, and in response to Cu chelation by
penicillamine (PCA) and dietary supplementation of the methyl donor betaine to modu-
late inflammatory and methylation status. Transcript levels of selected genes related to
endoplasmic reticulum stress, lipid synthesis, and fatty acid oxidation were down-regu-
lated at baseline in tx-j mice, further down-regulated in response to PCA, and showed little
to no response to betaine. Hepatic Sahh transcript and protein levels were reduced in tx-j
mice with consequent increase of SAH levels. Hepatic Cu accumulation was associated
with inflammation, as indicated by histopathology and elevated serum alanine amino-
transferase (ALT) and liver tumor necrosis factor alpha (Tnf-a) levels. Dnmt3b was down-
regulated in tx-j mice together with global DNA hypomethylation. PCA treatment of tx-j
mice reduced Tnf-a and ALT levels, betaine treatment increased S-adenosylmethionine
and up-regulated Dnmt3b levels, and both treatments restored global DNA methylation
levels. Conclusion: Reduced hepatic Sahh expression was associated with increased liver
SAH levels in the tx-j model of WD, with consequent global DNA hypomethylation.
Increased global DNA methylation was achieved by reducing inflammation by Cu chela-
tion or by providing methyl groups. We propose that increased SAH levels and inflamma-
tion affect widespread epigenetic regulation of gene expression in WD. (HEPATOLOGY
2013;57:555-565)
Abbreviations: CPT1A, carnitine palmitoyltransferase 1A; Cu, copper; DNMT, DNA methyltransferase; ER, endoplasmic reticulum; GRP78, glucose-regulated
protein 78; PCA, penicillamine; PPARa, peroxisome proliferator-activated receptor alpha; SAH, S-adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase;
SAM, S-adenosylmethionine; SREBP1c, sterol regulatory element-binding protein 1c; TNF-a, tumor necrosis factor alpha; WD, Wilson’s disease.
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T
he earliest phases of hepatic involvement in
Wilson’s disease (WD) include portal inflam-
mation that may present as lymphocyte and
neutrophil infiltrations,1 and microvesicular and mac-
rovesicular steatosis,2 which is exhibited both clini-
cally2 and in animal models of WD.3,4 Previous stud-
ies on the pathogenesis of WD explored the
possibilities of genetic polymorphisms in the ATP7B
copper (Cu) transporter,5 alternative ATP7B gene
splice variants,6 alterations in the RNA processing ma-
chinery,7 and the presence of gene modifiers.8 The
mechanisms connecting Cu accumulation to hepato-
cyte damage are poorly understood and may include
oxidative damage,9 apoptosis,10 and mitochondrial
membrane cross-linking.11
Abnormal methionine metabolism occurs in animal
models of hepatic Cu overload,12,13 is connected to epi-
genetic regulation of gene expression,14 and could repre-
sent a link between Cu accumulation and the variety of
hepatic manifestations in WD. Methionine metabolism
is central to the regulation of S-adenosylhomocysteine
(SAH), which inhibits methylation reactions, and is
known to sensitize hepatocytes to the presence of tumor
necrosis factor alpha (TNF-a).15 Similarly, by promot-
ing increased cell division and DNA repair, inflamma-
tion could increase the demand for methylation.16,17
SAH is the substrate for the bidirectional enzyme
SAH hydrolase (SAHH) (Supporting Material Fig.). Cu
may regulate methionine metabolism through its known
inhibitory effect on SAHH with consequent increase in
SAH, the principal inhibitor of transmethylation reac-
tions.12,13,18 Cu binds noncompetitively to the SAHH
enzyme and reduces its activity by releasing NADþ
cofactors.19 The regulatory role of increased Cu in
down-regulation of SAHH activity, with consequent ele-
vation of its substrate SAH and its potential secondary
epigenetic effects on gene expression, suggest that methi-
onine metabolism could be the missing link between Cu
accumulation and hepatocyte damage in WD. Of note,
there has been a growing interest in SAHH due to its
relationship with SAH levels and gene expression in he-
patic steatosis20 and human SAHH deficiency.21
We hypothesized that by regulating Sahh expression,
Cu and its associated hepatic inflammation initiate
alterations in methionine metabolism that affect DNA
methylation status and potentially the expression of
selected genes central to endoplasmic reticulum (ER)
stress and lipid metabolism in WD. To test this hy-
pothesis, we modulated Cu levels and inflammation by
administering the Cu chelator penicillamine (PCA)
and hepatic methylation status by administering the
methyl donor betaine in the tx-j mouse model of WD.
Materials and Methods
Animal Models and Experimental Protocols
We used the C3HeB/FeJ-Atp7btx-J/J mouse (tx-j)
model of WD with its background strain C3HeB/FeJ
(C3H) as a control. The tx-j mouse model has a
G712D missense mutation predicted to be in the sec-
ond transmembrane region of the Atp7B gene, which
results in a phenotypic disorder similar to WD.22 Mice
in the baseline and PCA experiments were obtained
from the Jackson Laboratory (Bar Harbor, ME),
whereas mice in the betaine experiments were obtained
from our in-house UC Davis colony that was developed
from C3H breeder pairs and homozygous-affected tx-j
breeder pairs purchased from the Jackson Laboratory.
At 24 weeks of age, seven males from each strain were
taken for harvest of blood and tissues and served as
control groups for mice in PCA and betaine studies.
PCA Study. From age 12 to 24 weeks, a subgroup
of seven male tx-j mice received treatment with oral
PCA (Sigma Aldrich, St. Louis, MO) that was dis-
solved in deionized water at 100 mg/kg bodyweight/
day, a dose shown to reduce hepatic Cu concentration
in a rat model of WD.23 PCA was not administered
to control mice since Cu deficiency could independ-
ently modify lipid24 and methionine metabolism.25
Betaine Study. From age 20 to 24 weeks, six male
C3H and seven tx-j mice were treated with betaine (Sigma
Aldrich) supplemented at 1.5% in the drinking water.26
All other methods are described in the Supporting
Material.
Results
Baseline Characteristics and Responses to PCA
and Betaine Treatments
Twenty-four-week-old tx-j mice had lower body
weights and higher liver/bodyweight ratios than
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control C3H mice (Table 1). Mean hepatic Cu con-
centration was more than 30 times increased in the tx-
j mice and was associated with marked lobular and
portal inflammation, with 6-fold increase in serum
alanine aminotransferase (ALT) levels and increased
liver Tnf-a transcript levels. There were no differences
in hepatic iron levels between the groups. Liver histo-
pathology of tx-j mice at 24 weeks of age showed lym-
phocytic lobular and portal infiltrates and perisinusoi-
dal fibrosis (Fig. 1). The oral provision of PCA to tx-j
mice from age 12 to 24 weeks resulted in 50% reduc-
tion of hepatic Cu and serum ALT levels, 90% reduc-
tion in liver Tnf-a expression, and concomitant
improvements of both lobular and portal infiltration,
whereas betaine treatment had no effect on Tnf-a tran-
scripts or serum ALT in tx-j mice, but significantly
lowered mean hepatic Cu levels in control mice by
61% and nonsignificantly lowered mean hepatic Cu
levels by 30% while reducing lobular inflammation
(Table 1). Hepatocyte and nuclear diameters and their
ratios and hepatocyte nuclear areas were increased in
tx-j mice, but were unchanged by either PCA or
betaine.
Selected Gene Expressions for ER Stress and Stea-
tosis. The transcript levels of selected genes related to
ER stress (glucose-regulated protein 78 [Grp78]), lipo-
genesis (sterol regulatory element-binding protein
[Srebp1c]), and fatty acid b oxidation (peroxisome pro-
liferator-activated receptor a [Ppara] and carnitine pal-
mitoyl transferase 1A [Cpt1A]), and protein levels of
SREBP1c and PPARa were each lower in untreated tx-
j than in C3H mice (Fig. 2). PCA further down-regu-
lated Srebp1c and Ppara transcript levels and protein
levels of GRP78 and CPT1A in tx-j mice. Betaine
down-regulated the transcript levels of Grp78, Ppara,
and Cpt1A in the control mice and Cpt1A in tx-j
mice, whereas both transcript and protein levels of
SREBP1c, PPARa, and CPT1A were each lower in be-
taine-treated tx-j mice than in betaine-treated control
mice.
Methionine Metabolism, DNA Methyltransferases,
and Global DNA Methylation in Untreated
tx-j Mice
Liver S-adenosylmethionine (SAM) levels were simi-
lar in the untreated groups, whereas SAH levels were
increased and SAM to SAH ratios were lower in the
tx-j mice versus control mice (Fig. 3A-C). Although
SAHH activity was similar in both untreated groups
(Fig. 3D), both SAHH gene and protein expressions
were decreased in the tx-j mice (Fig. 3F). DNA meth-
yltransferase 1 (Dnmt1) transcripts were up-regulated,
Dnmt3a transcripts were similar, and Dnmt3b tran-
scripts were down-regulated in tx-j mice (Fig. 4A-C).
According to dot blot analysis, global DNA methyla-
tion was lower in tx-j than in C3H mice (Fig. 5).
Effects of PCA on SAHH Activity, Tnf-a and
Dnmts Transcripts, and Global DNA Methylation
PCA treatment reduced Tnf-a transcripts by 10-fold
(Table 1) and increased SAHH activity in tx-j mice
(Fig. 3D), whereas Sahh gene expression remained low
and protein levels were further decreased (Fig. 3F),
although SAM and SAH levels and SAM/SAH ratios
were unchanged (Fig. 3A-C). PCA treatment restored
global DNA methylation to control levels (Fig. 5), de-
spite unchanged Dnmt1 and reduction of Dnmt3a and
Dnmt3b transcripts (Fig. 4B,C).
Table 1. Effects of Copper Accumulation, Penicillamine and Betaine Administration
Control (C3H) (7) Tx-j (7) Tx-j þ PCA (7) Control (C3H) þ betaine (6) Tx-j þ betaine (7)
Body weight (g) 39.562.4a 29.361.2a 27.861.8 40.561.41d 29.361.1d
Liver/body weight 0.04660.002a 0.05860.001a,b 0.05460.003b 0.04960.002d 0.0660.001d
Copper (liver) (lg/g d.w.) 7.261.5a,c 2596104a,b 125626b 2.860.4c,d 181613d
Iron (liver) (lg/g d.w.) 94.6610.8 100611 98.868.6 79.564.6 101613
ALT (plasma)(U/L) 36.2614.5a 238649a,b 104639.5b 34.869.1d 2346111d
Bilirubin (mg/dL) 0.3860.21 0.460.11b 0.360.17 0.160 0.1260.04b
Tnf-a liver transcripts (fold changes) -0.5661.4a 2.9161.26 a,b 0.2861.8 b -1.3461.4d 2.8561.1 d
Lobular inflammation (0-3) 060a 1.0860.5a,b 0.460.41a,b 060d 0.3760.25b,d
Portal inflammation (0-3) 0.1260.2a 1.6660.51a,b 1.160.22b 060d 1.7560.5d
Hepatocyte nuclear diameter (N) (lm) 5.660.2a 1662a 14.760.19 5.660.3d 1560.8d
Hepatocyte cell diameter (C) (lm) 16.960.9a 4164.8a 4061.8 17.461d 3862.9d
N/C ratio 0.360.01a 0.460.01a 0.460.01 0.360.007d 0.460.01d
Hepatocyte nuclear area (lm2) 4662.9a 9967.7a 114614 4760.62d 101619d
Values are expressed as mean 6 SD. In parenthesis, the number of mice in each group.
Values with same letter symbol are significantly different (P < 0.05) from each other. Hepatocyte nuclear and cell diameter were calculated on 4-6 mice/group.
The relative expression of Tnf-a (and other target genes in subsequent figures) was calculated using the equation 2DDCq where DDCq ¼ DCq(sample) 
DCq(calibrator). Gene transcription is expressed as an n-fold difference relative to the calibrator (mean of control groups). The chosen reference gene is HPRT1
(coefficient of variation¼ 3.3%). See Supporting Material for additional methods. PCA: penicillamine.
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Effects of Betaine Treatment on SAM/SAH Ratio,
Transcript Levels of Dnmt3b, and Global DNA
Methylation
Betaine treatment from 20 to 24 weeks increased
hepatic SAM levels in both groups, SAH levels in con-
trol mice, and the SAM/SAH ratio in tx-j mice (Fig.
3A-C). Although betaine treatment did not affect
SAHH activity (Fig. 3E), it down-regulated Sahh tran-
scripts in tx-j mice (Fig. 3F). Dnmt1 and Dnmt3a
transcripts were unchanged by betaine in both groups
(Fig. 4A,B), whereas Dnmt3b transcript levels were up-
regulated in tx-j mice (Fig. 4C). Global DNA methyl-
ation was increased by betaine treatment in both
groups (Fig. 5).
Correlations of Dnmts Transcript Levels with
Global DNA Methylation and Selected Gene Expres-
sions. Using data from all groups, Dnmt3b expression
correlated positively with global DNA methylation and
with transcript levels of Sahh, Grp78, Srebp1c, Ppara,
and Cpt1A (Table 2). In addition (not shown), global
DNA methylation values correlated with Srebp1c and
Ppara transcript levels (r ¼ 0.39, P ¼ 0.02 and r ¼
0.41, P ¼ 0.02, respectively).
Immunostaining for 5-Methylcytosine.
The immunostaining pattern for 5-methylcytosine
showed diffuse and less intense signals in hepatocyte
nuclei from tx-j mice than in C3H mice (Fig. 61A,2A).
Normalized signal intensity was significantly higher in
C3H mice than in tx-j mice, but not significantly dif-
ferent in betaine treated tx-j and control mice. In addi-
tion, when comparing betaine versus PCA treated tx-j
mice, betaine treatment was associated with stronger
nuclear intensity peaks (Fig. 62B,2C), indicating that
provision of methyl groups is associated with a differ-
ent pattern of DNA methylation.
Discussion
This study investigated the potential role of Cu-
induced abnormal methionine metabolism in the tx-j
mouse model of WD and found several novel results
relevant to treatment. First, elevated levels of SAH and
reduced levels of the SAM to SAH methylation ratio
were observed in untreated tx-j mice in association
with reduced levels of SAHH and global DNA meth-
ylation. DNA hypomethylation in tx-j mice was corre-
lated with reduced expression of Dnmt3b, but was par-
adoxically associated with increased expression of
Dnmt1. Second, Cu chelation by PCA improved
inflammation in the tx-j mice, reduced the expression
of Tnf-a and selected genes related to ER stress and
lipid metabolism, and normalized global DNA methyl-
ation levels while reducing transcript levels of Dnmt3a
and Dnmt3b. Lastly, the methyl donor betaine also
normalized global DNA methylation while enhancing
SAM levels and SAM-to-SAH ratio and reducing tran-
script levels of Cpt1A in the tx-j mice.
Fig. 1. Liver histology from control and tx-j mice at 24 weeks of age (A,B, hematoxylin and eosin, 10; A, central vein; B, portal space; C,
trichrome, 20). Control (C3H) mice histology was normal (panels 1 and 4). Untreated tx-j mice presented enlarged and glycogenated hepato-
cyte nuclei (arrows) (2A), with marked lymphocytic lobular (2A) and portal infiltrate (arrow) (2B) and perisinusoidal fibrosis (2C). Minimal steato-
sis was present and was unaffected by either treatment. Lobular inflammatory infiltrate partially improved after penicillamine (arrow) (3A) and
betaine treatment (arrow) (5A), with no change in portal inflammatory infiltrate after betaine treatment (arrow) (5B).
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We propose that interplay between inflammation
and methionine metabolism is related to Cu-mediated
inhibition of Sahh resulting in elevated SAH levels,
which dysregulates methylation status and gene expres-
sion in WD. We demonstrated that Sahh transcript
and protein levels were down-regulated in the tx-j
mouse model of WD, whereas SAHH activity was
increased by Cu chelation with PCA, although liver
SAH levels remained increased and the SAM/SAH
level decreased. A previous study on the natural course
Fig. 2. Western blot analysis and transcripts levels of genes representative of ER stress, lipogenesis, and fatty acid oxidation. ‘‘Control’’ refers
to untreated C3H mice in all panels. (A-D) GRP78; SREBP1c; PPARa; CPT1A, each showing protein and transcript expression data normalized to
b-actin (6-7 mice/group); (E) Numerical mean 6 SD of protein expressions according to Western blots, in parenthesis the number of mice used
for the quantification (seven in all groups, except CPT1A (†) in six tx-j mice) in this and subsequent figures. *P < 0.05; **P < 0.001. See
Supporting Information for methods. Values with the same letter symbol are significantly different (P < 0.05) from each other.
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Fig. 3. (A) Hepatic S-adenosylmethionine (SAM); (B) S-adenosylhomocysteine (SAH); (C) SAM/SAH ratio; (D,E) S-adenosylhomocysteine hy-
drolase (SAHH) activity; (F) Western blot analyses and mRNA transcript levels. The curves for SAHH activities in C3H and tx-j mice represent the
average of absorbance measurements of 6-7 mice from each group of 24-week-old mice, untreated and in response to penicillamine (PCA) (D)
and betaine (E). Protein and gene transcript levels of SAHH were significantly lower in tx-j mice compared to control CH3 mice (F). Values with
the same letter symbol are significantly different (P < 0.05) from each other. *P < 0.05; **P < 0.001.
of WD in 24-week-old LEC rats showed reduced
SAHH protein levels only in advanced stages of liver
disease,27 in contrast to findings in the present study
of the same age tx-j mice.
SAH is a potent inhibitor of DNMTs activities and
reduced levels of Dnmts transcripts were described in
response to elevated SAH levels in a recent clinical
study.28 Notably, we observed that Dnmt1, which enc-
odes the principal DNMT in mammalian cells and is
mainly implicated in the maintenance of methylation
status, was up-regulated, whereas Dnmt3b, encoding a
de novo methyltransferase, was down-regulated in
untreated tx-j mice, and both Dnmt3a and Dnmt3b
transcripts were down-regulated by PCA. Transcript
levels of Dnmt genes show compensatory increased lev-
els in response to reduced DNA methylation in liver
or brain.29 Others described up-regulation of Dnmt1
expression without changes in Dnmt3a in livers of
choline-deficient rat embryos with global DNA hypo-
methylation,30 whereas Dnmts levels are increased in
chronic hepatitis, cirrhosis, and human hepatocellular
carcinoma.31 The finding that Dnmt3b was down-
regulated in untreated tx-j mice with increased SAH
levels and correlated with global DNA methylation
and expressions of each of the studied genes suggests
that this enzyme plays a major role in controlling
global DNA methylation in WD. There were some
discrepancies in the Dnmts expression in response to
betaine treatment. We did not observe any change in
Dnmts levels in control mice nor in Dnmt1 and
Dnmt3a in tx-j mice, whereas Dnmt3b was markedly
up-regulated in tx-j mice in response to betaine.
Tx-j mice demonstrated reduced levels of global
DNA methylation, which was restored either by PCA-
induced Cu chelation or by provision of the methyl
donor betaine. The positive effect of PCA on increas-
ing global DNA methylation may be due to relatively
reduced inflammation and demand for methyl
groups.17 At the same time, methyl group supplemen-
tation by betaine could increase global DNA methyla-
tion in both control and tx-j mice, regardless of
inflammation. We propose that global DNA hypome-
thylation in WD was influenced by inflammation
which was resolved by reducing Cu hepatic levels by
PCA treatment, or by the increasing availability of
methyl groups by betaine. The major difference
between PCA and betaine treatment in tx-j mice was
that PCA was exclusively associated with a significant
improvement of inflammation, whereas only betaine
induced significant increased SAM and Dnmt3b levels.
These observations suggest a potential positive additive
effect of including betaine in the PCA treatment of
patients with WD.
Methyl donors such as betaine and/or SAM have
been used effectively in treatment of other liver dis-
eases, including adjuvant therapy for hepatitis C in
which either agent restored methylation of STAT1
which regulates the response to interferon treatment,32
whereas SAM improved viral kinetics by increasing the
methylation of STAT1 and the expressions of its repre-
sentative genes.33 A study of experimental acetamino-
phen liver toxicity found that SAM administration
restored its mitochondrial and nuclear levels, possibly
due to increased expression and activity of methionine
adenosyltransferase.34 These results support our find-
ings that the administration of the methyl donor beta-
ine modified SAM levels and consequently the expres-
sions of selected genes.
The observed significant 61% reduction of the
mean liver Cu level by betaine treatment in control
mice and nonsignificant 30% reduction of mean he-
patic Cu level in the tx-j mice (Table 1) are original
findings, which could have been influenced by uneven
hepatic Cu distribution in the liver.35 Potentially,
Fig. 4. DNA methyltransferases transcript levels. Dnmt1 levels were
up-regulated (A), whereas Dnmt3b (C) levels were down-regulated in
untreated tx-j mice and further down-regulated by PCA treatment in
both Dnmt3a and Dnmt3b. Betaine treatment had opposite effects on
Dnmt1 and Dnmt3b expression in control and tx-j mice, while increas-
ing the expression of Dnmt3b in the treated tx-j mice. *P < 0.05;
**P < 0.001.
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betaine could reduce Cu levels by modification of the
expressions of genes for Cu chaperones or cellular
transport. Ultimately, only long-term studies on beta-
ine treatment for tx-j mice may clarify this issue.
Currently, the molecular mechanisms linking Cu
and gene expression are unknown but it seems likely
that methylation plays an important role. Reduced
global methylation in the untreated tx-j mice could
relate to increased inflammation, which others have
associated with increased demand for gene methylation
resulting from increased cell division and DNA.16,17
Consequently, WD may be associated with increased
demand for methyl groups as result of both an increase
of the methylation inhibitor SAH and increased
inflammation. Although the associations of Cu-medi-
ated SAHH inhibition with SAH accumulation and
reduced Dnmt3b transcripts were consistent with
global DNA hypomethylation in tx-j mouse livers, the
relationship between DNA hypomethylation and
down-regulation of the expressions of genes representa-
tive of ER stress, lipogenesis, and fatty acid oxidation
in untreated tx-j mice is less clear. Similar to our data,
others described down-regulation of gene transcripts
representative of lipid metabolism in the Atp7b/
Fig. 5. Global DNA methylation. (A) Global DNA methylation was lower in the tx-j mice and improved to control levels after Cu chelation by
PCA. Betaine treatment resulted in increased methylation in both untreated groups. (B) The red blots represent 5-methylcytosine (5-MeC) and
the green blots represent total DNA signal. Each timepoint and genotype is represented by two mice (upper and lower row in each black square),
each of them in triplicate. Each blot represents methylated DNA from one mouse. *P < 0.05; **P < 0.001.
Table 2. Correlation Analysis of the Relationship Between Dnmts Transcript Levels with Global DNA Methylation and the
Expressions of the Studied Genes
Global DNA
methylation Sahh Grp78 Srebp1c Ppara Cpt1A
r P value r P value r P value r P value r P value r P value
Dnmt1 -0.19 0.30 -0.29 0.13 -0.01 0.97 0.30 0.10 0.05 0.77 0.04 0.82
Dnmt3a 0.07 0.70 0.18 0.35 0.39 0.04 0.71 <0.0001 0.67 <0.0001 0.54 0.002
Dnmt3b 0.48 0.006 0.46 0.01 0.44 0.02 0.78 <0.0001 0.79 <0.0001 0.47 0.01
Sahh, S-adenosylhomocysteine hydrolase; Grp78, glucose-related protein 78; Srebp1c, sterol regulatory element-binding protein 1c; Ppara, peroxisome prolifera-
tor-activated receptor a; Cpt1A, carnitine palmitoyltransferase 1A; Dnmt, DNA methyltransferase.
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knockout mouse at 6 weeks of age, prior to develop-
ment of histological damage.36 However, this study did
not find any changes in Sahh and Dnmt1 expressions,
whereas Dnmt3a, Dnmt3b, and potential changes in
lipid metabolism in response to Cu chelation were not
measured. In the present study, the hypothesis that the
observed changes in gene transcript levels with PCA
treatment are due to changes in methylation is sup-
ported by observations that both PCA and betaine
treatments were associated with significant increases in
global DNA methylation and by the positive correla-
tions between Dnmt3b transcripts and global DNA
methylation and transcripts of genes representative of
ER stress, lipogenesis, and fatty acid oxidation.
There are potentially other mechanisms involved in
the gene expression response to Cu accumulation and
PCA. As discussed by others, various proteins could
mediate crosstalk between Cu status and lipid metabo-
lism,37 and others showed that Cu enters nuclei where
it can bind to specific targets.38
The observed changes in hepatocellular morphology
with increased hepatocyte and nuclear diameter, and nu-
clear to hepatocyte diameter ratios that persisted with
treatment, are novel, and differ from previously reported
data in the LEC rat where they responded to Cu chela-
tion therapy.23 Nuclear and cellular hepatocyte enlarge-
ment, which in general are associated with chronic hepa-
titis with hepatocyte enzymatic activation,39 is well
known in humans with WD1,40 and in animal models of
this condition3,23 but the response to Cu chelation treat-
ment has not been consistently described.41
Prior studies on the effects of betaine included its
down-regulation of selected ethanol-induced ER stress-
related genes Grp78 and Srebp1c in mice,42 that Ppara
promoter methylation in offspring was affected by
maternal dietary betaine in rats,43 and that the Cpt1A
promoter is hypermethylated in human embryonic stem
cells.44 Although both PCA and betaine treatments were
associated with increased global DNA methylation in
our study, betaine treatment achieved significant down-
regulation of selected ER stress and fatty acid oxidation
related transcripts only in control mice, i.e., specifically
in the absence of inflammation and Cu accumulation.
Increased methylation of promoter CpG islands has
been correlated with gene silencing, and may be occur-
ring in our control mice with normally saturated levels
Fig. 6. Immunostaining for 5-methylcytosine. Compared to C3H mice (1A), untreated tx-j mice presented diffuse and less intense nuclear
staining (2A) (P < 0.01). Betaine-treated control (1B) and tx-j mice (2C) had similar immunostaining patterns. Betaine-treated tx-j (2C) pre-
sented a higher percentage of nuclear peaks than PCA-treated tx-j mice (2B) (P ¼ 0.01). Arrowheads in the insets indicate representative
nuclei.
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of DNA methylation following betaine treatment. In
contrast, gene body and intergenic methylation were un-
saturated in the global hypomethylated state that we
observed in the tx-j mouse livers, so increasing the avail-
ability of methyl groups can be predicted to target non-
promoter methylation sites associated with increased
gene expression levels.45 Of note, the directions and
magnitude of changes in proteins levels for the studied
genes were generally similar to those in transcript levels.
It is possible that the observed differences between mes-
senger RNA (mRNA) and protein levels of several of the
studied genes could be attributed to posttranslational
modifications.
In summary, WD appears to be a condition associ-
ated with increased demand for methyl groups due to
both increased levels of the methylation inhibitor
SAH, which is based on the inhibitory effect of Cu
on SAHH as shown by its activation after PCA chela-
tion, and also due to chronic inflammatory status
(Supporting Fig.). Our results demonstrate reduced
SAHH levels in a mouse model of WD that is char-
acterized by Cu accumulation and hepatic inflamma-
tion in the early phases of liver damage. The conse-
quent elevation of liver SAH as a result of SAHH
inhibition, and the concomitant inflammation, were
associated with down-regulation of Dnmt3b and
global DNA hypomethylation. Our study supports
the hypothesis that gene expression and possibly phe-
notypic presentations of WD are affected by interac-
tions between Cu accumulation and methionine
metabolism.
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